Actuate reports preclinical synergy of elraglusib with RAS inhibitors in pancreatic cancer models - ACTU News | RalliesActuate reports preclinical synergy of elraglusib with RAS inhibitors in pancreatic cancer models
A
ACTU• Preclinical pancreatic cancer results
- Actuate Therapeutics disclosed new preclinical studies in pancreatic cancer combining elraglusib with RAS inhibitors zoldonrasib or daraxonrasib.
- Work showed stronger anti-tumor effects for the combinations than either drug alone across multiple murine and human models.
- Separate tests in chemotherapy-resistant models also indicated improved activity for elraglusib with zoldonrasib versus single-agent treatment.
- Additional study results will be presented at upcoming medical conferences.
IRD
•
